Differences in Clinical Outcomes and Survival Among Primary, Secondary, and Concomitant Carcinoma In Situ of the Bladder.

bacillus calmette–guérin bladder cancer carcinoma in situ transurethral resection of bladder tumor (turbt) urothelial carcinoma

Journal

Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737

Informations de publication

Date de publication:
Sep 2024
Historique:
accepted: 17 09 2024
medline: 21 10 2024
pubmed: 21 10 2024
entrez: 21 10 2024
Statut: epublish

Résumé

Carcinoma in situ (CIS) is a flat, high-grade, and aggressive form of urothelial carcinoma with a high risk of progression to muscle-invasive disease and metastasis. This study aimed to investigate differences in clinical outcomes and survival among patients with primary, secondary, and concomitant CIS of the bladder. A total of 209 patients diagnosed with CIS between 2010 and 2022 in our department with a minimum follow-up of 12 months were retrospectively analyzed. Patients with muscle-invasive cancer at diagnosis, those with recurrence within one month after diagnosis, and those with primary malignant melanoma were excluded. The recurrence, progression, and cancer-specific mortality rates of patients receiving Bacillus Calmette-Guérin therapy for CIS were analyzed. A total of 96 patients with primary ( Secondary CIS had a significantly higher recurrence rate than concomitant CIS. However, no statistically significant association was observed between CIS subtypes and RFS or PFS.

Identifiants

pubmed: 39429268
doi: 10.7759/cureus.69625
pmc: PMC11487294
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e69625

Informations de copyright

Copyright © 2024, Hata et al.

Déclaration de conflit d'intérêts

Human subjects: Consent was obtained or waived by all participants in this study. Institutional Review Board of Oita University issued approval 2358. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Auteurs

Shinro Hata (S)

Department of Urology, Faculty of Medicine, Oita University, Yufu, JPN.

Hiroyuki Fujinami (H)

Department of Urology, Faculty of Medicine, Oita University, Yufu, JPN.

Mayuka Shinohara (M)

Department of Urology, Faculty of Medicine, Oita University, Yufu, JPN.

Shinya Sejiyama (S)

Department of Urology, Faculty of Medicine, Oita University, Yufu, JPN.

Toru Inoue (T)

Department of Urology, Faculty of Medicine, Oita University, Yufu, JPN.

Hiromitsu Mimata (H)

Department of Urology, Faculty of Medicine, Oita University, Yufu, JPN.

Toshitaka Shin (T)

Department of Urology, Faculty of Medicine, Oita University, Yufu, JPN.

Classifications MeSH